Zolgensma launched in May 2019 in the US for $2.1 million, whilst Zynteglo was launched in the EU in...
Read moreThis study aimed to compare the use of financial agreements for oncology and non-oncology appraisals...
Read moreThis study from 2017 - 2019 compares the outcomes for oncology and non-oncology appraisals conducted...
Read moreIn England, to gain a positive recommendation for use within the NHS from NICE, pharmaceutical produ...
Read moreA targeted drug has been accepted for routine use on the NHS in England for some adults with untreat...
Read moreBy joining together, countries can combine their resources to potentially increase the efficiency of...
Read morePharmaceutical pricing and market access is the crucial challenge for successful product launch toda...
Read moreWhat is the future of precision medicine in the EU? The field of precision medicine is a complex are...
Read moreNICE will continue to offer joint advice with the Medicines and Healthcare products Regulatory Agenc...
Read moreThe law provides a legal framework for the automatic substitution of biosimilars at the level of the...
Read more